"GLP-3" is an informal term for investigational triple-agonist medications (like retatrutide) that target three metabolic pathways: GLP-1, GIP, and glucagon receptors. Benefits include up to 24% - 30% average weight loss, near-total clearance of liver fat, and reductions in joint pain